CN102015753A - 乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途 - Google Patents

乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途 Download PDF

Info

Publication number
CN102015753A
CN102015753A CN2009801125069A CN200980112506A CN102015753A CN 102015753 A CN102015753 A CN 102015753A CN 2009801125069 A CN2009801125069 A CN 2009801125069A CN 200980112506 A CN200980112506 A CN 200980112506A CN 102015753 A CN102015753 A CN 102015753A
Authority
CN
China
Prior art keywords
hydrophobically modified
liver
derived peptide
pres
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801125069A
Other languages
English (en)
Chinese (zh)
Inventor
W·米尔
U·哈伯科恩
S·乌尔班
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsklinikum Heidelberg
Original Assignee
Universitaetsklinikum Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Heidelberg filed Critical Universitaetsklinikum Heidelberg
Publication of CN102015753A publication Critical patent/CN102015753A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6036—DNA rev transcr viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801125069A 2008-01-25 2009-01-26 乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途 Pending CN102015753A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6234708P 2008-01-25 2008-01-25
US61/062347 2008-01-25
PCT/EP2009/000477 WO2009092612A1 (en) 2008-01-25 2009-01-26 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as vehicles for the specific delivery of compounds to the liver

Publications (1)

Publication Number Publication Date
CN102015753A true CN102015753A (zh) 2011-04-13

Family

ID=40521848

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801125069A Pending CN102015753A (zh) 2008-01-25 2009-01-26 乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途

Country Status (6)

Country Link
US (1) US9868768B2 (enExample)
EP (1) EP2245047B1 (enExample)
JP (1) JP5686468B2 (enExample)
CN (1) CN102015753A (enExample)
ES (1) ES2847288T3 (enExample)
WO (1) WO2009092612A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103665095A (zh) * 2012-09-11 2014-03-26 中国人民解放军军事医学科学院卫生学环境医学研究所 一种疏水性多肽修饰抗体的合成方法
CN108367047A (zh) * 2015-12-16 2018-08-03 鲁普莱希特-卡尔斯-海德堡大学 环状ntcp靶向肽及其作为进入抑制剂的应用
CN108721599A (zh) * 2017-04-18 2018-11-02 Myr有限公司 使用htcp抑制剂的疗法
CN109354623A (zh) * 2012-04-25 2019-02-19 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
CN111499722A (zh) * 2012-11-12 2020-08-07 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽
WO2025031397A1 (zh) * 2023-08-08 2025-02-13 前沿生物药业(南京)股份有限公司 钠离子-牛磺胆酸共转运蛋白长效抑制剂及其应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281761A1 (en) 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
EP2117576B1 (en) 2007-02-08 2014-04-16 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US8875361B2 (en) 2008-05-21 2014-11-04 Wirtz Manufacturing Co., Inc. Reformed battery grids
SG178254A1 (en) * 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
CN102241744B (zh) * 2010-05-14 2015-03-04 上海贺普药业股份有限公司 一种病毒感染阻断剂、其药物组合物及其应用
WO2012106403A2 (en) * 2011-02-01 2012-08-09 Uab Research Foundation Methods and compositions for pseudoinfectious alphaviruses
CN103402545B (zh) * 2011-02-10 2017-04-05 海德堡鲁普雷希特卡尔斯大学 疏水性经修饰肽及其在肝特异性靶向中的用途
US10363323B2 (en) 2011-02-10 2019-07-30 Ruprecht-Karls-Universitat Heidelberg Hydrophobic modified peptides for liver specific diagnosis
EP2691105B1 (en) 2011-03-28 2018-07-11 University of Utah Research Foundation Methods and compositions related to inhibition of viral entry
EP2703001A1 (en) 2012-08-26 2014-03-05 XAX Kft. Tumor vaccination
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
ES2922883T3 (es) * 2014-10-07 2022-09-21 Myr Gmbh Tratamiento combinado de la infección por VHB y VHD
EP3138579A1 (en) * 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
EP3189850A1 (en) * 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv
CN109069577B (zh) 2016-01-07 2022-08-19 纳维根公司 Hiv进入的d-肽抑制剂以及使用方法
WO2018054891A1 (en) 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Compounds and combinations thereof for preventing and/or treating hbv and/or hdv infections
CN109718364A (zh) * 2017-10-27 2019-05-07 上海贺普药业股份有限公司 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
EP3804750A1 (en) 2019-10-10 2021-04-14 Universität Heidelberg Conjugate compounds for preventing and/or treating hbv and/or hdv infections, liver diseases and for targeting ntcp
WO2021168575A1 (en) * 2020-02-27 2021-09-02 Quadrumix Biotechnology Inc. Polypeptides directed against viral infection and uses thereof
JP2024535127A (ja) 2021-09-14 2024-09-26 アドファファーム ゲーエムベーハー 新規リポペプチド製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204096A (en) * 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
EP1281761A1 (en) * 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
WO2008103380A2 (en) * 2007-02-21 2008-08-28 Fox Chase Cancer Center Hepatitis b virus compositions and methods of use

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109354623A (zh) * 2012-04-25 2019-02-19 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
CN109354623B (zh) * 2012-04-25 2022-06-24 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
CN103665095A (zh) * 2012-09-11 2014-03-26 中国人民解放军军事医学科学院卫生学环境医学研究所 一种疏水性多肽修饰抗体的合成方法
CN111499722A (zh) * 2012-11-12 2020-08-07 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽
CN108367047A (zh) * 2015-12-16 2018-08-03 鲁普莱希特-卡尔斯-海德堡大学 环状ntcp靶向肽及其作为进入抑制剂的应用
CN108721599A (zh) * 2017-04-18 2018-11-02 Myr有限公司 使用htcp抑制剂的疗法
WO2025031397A1 (zh) * 2023-08-08 2025-02-13 前沿生物药业(南京)股份有限公司 钠离子-牛磺胆酸共转运蛋白长效抑制剂及其应用

Also Published As

Publication number Publication date
EP2245047A1 (en) 2010-11-03
JP5686468B2 (ja) 2015-03-18
ES2847288T3 (es) 2021-08-02
US20110027183A1 (en) 2011-02-03
WO2009092612A1 (en) 2009-07-30
EP2245047B1 (en) 2020-11-18
JP2011512123A (ja) 2011-04-21
US9868768B2 (en) 2018-01-16

Similar Documents

Publication Publication Date Title
US9868768B2 (en) Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as vehicles for the specific delivery of compounds to the liver
AU2009207806B2 (en) Hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) and their use as HBV and HBV entry inhibitors
CN103402545B (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
JP2022022455A (ja) 環状ｎｔｃｐ標的化ペプチドおよび侵入阻害剤としてのその使用
JP2017081952A (ja) 肝臓特異的診断のための疎水性修飾ペプチド
JP2021500411A (ja) 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法
EP3189850A1 (en) Liver targeting of cyclic pres-derived peptides of hbv
HK1150168B (en) Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20110413

RJ01 Rejection of invention patent application after publication